Amarantus Therapeutics makes board appointment
This article was originally published in Scrip
Amarantus Therapeutics, a privately held US biotech company developing first-in-class disease-modifying treatments that address the underlying cause of apoptosis associated with a wide range of diseases, has appointed Dr Lawrence Schwartz to its scientific advisory board. He is director of the Center of Excellence in Apoptosis Research, founding director of the Pioneer Valley Life Sciences Institute and professor of biology at the University of Massachusetts Amherst.
You may also be interested in...
Device Week, 9 July 2020 –Transcatheter MV Repair CMS Coverage Update; Chats With Boston Scientific, Protaryx
In this week’s podcast, Medtech Insight's managing editor Marion Webb chats with editor-in-chief Phil Greenfield about start-up Protaryx Medical, which raised $8.3m to develop a universal catheter system for delivering beating heart treatments. Deputy editor Reed Miller discusses proposed updates by the Centers for Medicare and Medicaid Services for coverage of transcatheter mitral valve repair and reporter Catherine Longworth talks about her Exec Chat on digital transformation in health care with Boston Scientific's Angelo De Rosa.
Iranian researchers found using 500 mg curcumin complex daily for seven days reduced levels of leptin, which can promote inflammatory response, in patients with traumatic brain injury. In study published in Phytotherapy Research, 28 subjects had an overall 47.1% reduction in leptin.
Under a new proposed rule from the CMS, home health agencies could be reimbursed by Medicare for telemedicine services provided to homebound beneficiaries.